Spago Nanomedical AB (SE:SPAGO)

:SPAGO

SPAGO

Spago Nanomedical AB

RESEARCH TOOLSreports

Spago Nanomedical AB (SPAGO) Price & Analysis

0 Followers

SPAGO Stock Chart & Stats

kr0.10

kr0.00(0.00%)

At close: Mar 06 4:00 PM EST

kr0.10

kr0.00(0.00%)

Day’s Range― - ―

52-Week Rangekr0.06 - kr0.33

Previous CloseN/A

Volume33.85K

Average Volume (3M)1.01M

Market Cap

kr70.13M

Enterprise Valuekr9.65M

Total Cash (Recent Filing)kr29.67M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta1.05

Next Earnings

May 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding661,572,800

10 Day Avg. Volume1,158,815

30 Day Avg. Volume1,005,829

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)1.42

Price to Sales (P/S)99.92

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.04

Revenue Forecast (FY)kr1.00M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero reported debt materially reduces financial distress risk and preserves strategic optionality for a pre-revenue biotech. Over 2–6 months this lowers near-term refinancing pressure, enabling management to prioritize R&D progress, partner discussions, or staged financing rather than urgent debt servicing.

Focused Pipeline (SpagoPix & Tumorad)A clear, focused technology platform (nanoparticle imaging and theranostics) concentrates resources on two complementary programs. This specialization supports durable competitive positioning in imaging/theranostics markets and makes the company an attractive partner or collaborator for larger pharma and diagnostic firms.

Narrowing Net LossesSustained reduction in net losses indicates improving operating efficiency or controlled spending, which, if continued, lengthens runway and reduces dilution risk from capital raises. Over months this trend strengthens credibility with investors and potential partners evaluating long-term collaboration.

Bears Say

Persistent Cash BurnOngoing negative operating cash flow demonstrates structural cash consumption from R&D and operations, creating repeated dependence on external financing. Over a multi-month horizon this raises execution risk, potential funding dilution, and constrains the pace of clinical development without new capital or partnerships.

Volatile, Falling RevenueHighly volatile and sharply declining revenue signals limited commercial traction and fragile non-R&D income streams. In the medium term this reduces internal funding capacity, increases reliance on capital markets or partners, and weakens the company’s ability to self-fund pivotal trials or scale later-stage programs.

Eroding Equity And Negative ROEDeclining equity and persistently negative ROE reflect shareholder value erosion from repeated losses. Structurally this constrains future financing options, may pressure governance decisions, and can deter long-term investors or strategic partners assessing balance sheet strength over a multi-month horizon.

SPAGO FAQ

What was Spago Nanomedical AB’s price range in the past 12 months?

Spago Nanomedical AB lowest stock price was kr0.06 and its highest was kr0.33 in the past 12 months.

What is Spago Nanomedical AB’s market cap?

Spago Nanomedical AB’s market cap is kr70.13M.

When is Spago Nanomedical AB’s upcoming earnings report date?

Spago Nanomedical AB’s upcoming earnings report date is May 07, 2026 which is in 35 days.

How were Spago Nanomedical AB’s earnings last quarter?

Spago Nanomedical AB released its earnings results on Feb 05, 2026. The company reported -kr0.013 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.013.

Is Spago Nanomedical AB overvalued?

According to Wall Street analysts Spago Nanomedical AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Spago Nanomedical AB pay dividends?

Spago Nanomedical AB does not currently pay dividends.

What is Spago Nanomedical AB’s EPS estimate?

Spago Nanomedical AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Spago Nanomedical AB have?

Spago Nanomedical AB has 661,572,800 shares outstanding.

What happened to Spago Nanomedical AB’s price movement after its last earnings report?

Spago Nanomedical AB reported an EPS of -kr0.013 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.695%.

Which hedge fund is a major shareholder of Spago Nanomedical AB?

Currently, no hedge funds are holding shares in SE:SPAGO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Spago Nanomedical AB

Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.